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Abstract: The Non-Structural 1 (NS1) protein is a multifactorial protein of type A influenza 
viruses that plays an important role in the virulence of the virus. A large amount of what we 
know about this protein has been obtained from studies using human influenza isolates and, 
consequently, the human NS1 protein. The current global interest in avian influenza, 
however, has highlighted a number of sequence and functional differences between the 
human and avian NS1. This review discusses these differences in addition to describing 
potential uses of NS1 in the management and control of avian influenza outbreaks. 
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1. Introduction 
The NS1 protein of influenza A viruses has been attracting a lot of attention recently given its 
multifunctional role and association with the virulence of the virus. The long list of functional 
characteristics and interactors of NS1 have been reviewed extensively by Krug et al. [1], Lin et al. [2] 
and more recently by Hale et al. [3] and are not the scope of this review. These authors have 
concentrated primarily on the NS1 from human isolates since, prior to the 1997 Hong Kong H5N1 
outbreak, there was very little information available on the NS1 of avian influenza isolates. This has 
changed, dramatically over the last decade and now, thanks to several influenza genome sequencing 
projects the influenza scientific community is in a situation whereby the genetic characteristics of 
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influenza A from different species can be compared [4-6]. Such comparisons between human and 
avian influenza viruses highlight a number of important and noteworthy differences that are discussed 
below.  
The NS1 protein has also been investigated by various groups to determine its possible use in AI 
vaccine development. In addition, the protein has been studied as a possible candidate for use in  
so-called DIVA (Differentiation of Infected from Vaccinated Animals) strategies in the control of AI. 
Both approaches will be discussed. 
2. Comparison between the NS1 of human and avian influenza viruses 
2.1. Structural differences 
The NS1 protein can be separated into distinct domains. The first 73 amino acids (aa) of the protein 
form a double-stranded RNA binding domain that counteracts the host immune response by blocking 
the synthesis of type I interferon. The carboxy terminal effector domain interacts with a number of 
cellular proteins and contains both nuclear export and import sequences along with a recently 
described nucleolar localization sequence [1-3]. The C-terminal domain has also been implicated in the 
enhancement of NS1's interferon antagonist properties by stabilizing its dimeric structure, a 
prerequisite for RNA binding [7,8] 
Several groups have reported the resolution of the three dimensional structure of either the RNA 
binding or the effector domain of NS1 [9-12] but it was Bornholdt and Prasad [13] who finally 
managed to resolve the complete structure at the end of 2008 by introducing two mutations (R38A and 
K41A) into the recombinant NS1 that prevented aggregation of the protein at the protein 
concentrations required for crystallographic studies. The report by Bornholdt and Prasad [13] provided 
the influenza community with possible explanations to several unanswered questions regarding NS1. 
In brief, their crystallographic analysis revealed that the NS1 molecules associate with each other to 
form a tubular structure that allows the protein to sequester double stranded RNA of varying lengths 
while at the same time interacting with other host proteins through binding sites on the outer surface. 
This explains how the protein can simultaneously perform the many tasks ascribed to it.  
Prior to the resolution of the full NS1 structure, a comparison of the X-ray crystallographic 
structure of the effector domain of an avian NS1 from A/Duck/Albany/76 was undertaken by   
Hale et al. [8]. The resolved structure was compared to the effector domain structure of a human 
influenza virus A/Puerto Rico/8/34 previously resolved by Bornholdt and Prasad [14] and a number of 
differences were identified. These included a difference in the orientation of a -hairpin between the 
viruses. This -hairpin is also referred to as the 140-loop and as yet no biological function has been 
associated to it although residues close to the loop have been implicated in the nuclear export of NS1 
into the cytoplasm of the host cell [15]. A second orientation difference between the two viruses was 
also identified at residue Tyr-89 which is involved in the NS1-mediated binding of phosphoinositide  
3-kinase (P13K) [16] although no functional difference was observed [10,16]. Finally, Trp-187 
implicated in the binding of the 30kDA subunit of the cleavage and polyadenylation factor (CPSF30) 
also adopted a different orientation between the two structures [17]. Interestingly, with reference to 
Trp-187, previous work has shown that the CPSF30-binding site on the NS1 of A/Duck/Albany/76 is 
functional while the human isolate A/Puerto Rico/8/34 does not interact with CPSF30 [18,19]. Viruses 2009, 1                      
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Nevertheless and despite these interesting findings, A/Puerto Rico/8/34 is a laboratory strain which 
may not completely represent other wild-type human viruses so care must be taken in drawing 
conclusions until the resolution of further NS1 structures from both avian and human viruses are 
undertaken and then compared at both a functional and structural level. 
2.2. Sequence differences  
Based on their amino acid sequence the NS1 of influenza A viruses can be divided into two groups 
refereed to as alleles, a term coined in 1989 by Treanor et al. [20]. The homology between the two 
alleles can be as low as 62%. The allele B group is made up exclusively of NS1 proteins from avian 
influenza viruses while allele A consists of proteins from both avian and mammalian sources. Studies 
have shown that allele A viruses have a replicative advantage in mammalian hosts and that they are 
under continual selection pressure as opposed to allele B viruses [21]. There are no reports of 
functional differences associated with the different alleles to date. The structural differences described 
above between human and avian NS1s may be due to the fact that the NS1 of A/Duck/Albany/76 is 
from  
allele B. Therefore the future resolution of the complete structure of an allele A NS1 would be of 
particular interest. 
2.3. Deletions 
The highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype have emerged as a 
devastating pathogen of poultry in Asia, Europe and Africa. The NS1 protein of this highly pathogenic 
virus has been shown to posses a unique 5 aa deletion (15 nucleotides) at position 80 to 84 resulting in 
a protein that is 5 aa shorter than the normal 230 for avian influenza NS1s. An analysis of the public 
sequence databases reveals that this deletion emerged in H5N1 isolates in 2000 and has persisted ever 
since outlasting H5N1 viruses with a 230 aa NS1 protein. Indeed, the last H5N1 NS1 without the 5 aa 
deletion was isolated in Kazakhstan in 2006 (Genbank ACJ53834). This would suggest that the 
deletion confers an, as yet, unidentified advantage on the viruses that possess them.  
The H5N1 virus (A/Viet Nam/1203/2004) used by Bornholdt and Prasad to resolve the 3D structure 
of NS1 possesses the 5 aa deletion [13]. The deletion is located in the linker region between the  
N-terminal RNA-binding domain and the C-terminal effector domain of the protein and so Bornholdt 
and Prasad suggest that it may allow for modulation of NS1’s affinity for dsRNA by influencing the 
positioning of the RNA-binding domain dimers. The deletion could also explain the observed 
conformational changes observed between the RNA-binding domain of the H5N1 virus and those of 
the H1N1 and H3N1 which do not possess the 5 aa deletion [13].  
Long et al. [22] have attempted to associate a biological significance to this deletion by generating 
recombinant viruses with and without the 15 nt deletion and experimentally infecting both chickens 
and mice. Their results demonstrated that in association with a D92E shift, previously shown to confer 
resistance to antiviral cytokines in a pig model [23], that the 15 nt deletion contributed to the virulence 
of the recombinant viruses in both animal models. However, since the increased virulence observed 
was always associated with the D92E shift and could not be conferred on a virus with an Asparagine at Viruses 2009, 1                      
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position 92, there is debate as to whether the observations reported were due to the 15 nt deletion or 
not [3]. 
2.4. Binding domains 
A large scale sequence analysis of avian influenza viruses revealed that the c-terminal four residues 
of the NS1 protein is a potential PDZ domain ligand [24]. PDZ domains are recognition modules that 
organize a variety of cell-signaling assemblies and it has been speculated that binding of these domains 
by NS1 might interfere with host cell signaling [25]. It was clearly shown by Obenauer et al. [24] that 
avian-like NS1 c-terminal residues (ESEV or EPEV) bind human PDZ domain-containing proteins 
while human c-terminal residues do not. A second study by Jackson et al. [26] employed reverse 
genetics to demonstrate that avian-like c-terminal residues modulate pathogenicity in a mouse model.  
The majority of avian influenza viruses have been shown to possess a glutamic acid (E) at amino 
227 of the NS1 protein compared to human isolates which contain an arginine (R) [27].   
Finkelstein et al. [28] observed that the H1N1 that caused 1918 “Spanish flu” pandemic had a K at 
amino acid 227 and more recently this lysine residue has also been identified in H5N1 AI viruses 
isolated from the Kingdom of Saudi Arabia and H9N2 viruses from Israel [29] (Genbank). This 
mutation is therefore being considered by some groups as an important marker of viruses that may 
pose a public health threat.  
It has been reported by Heikkinen et al. [30] that class II SH3-binding motifs are commonly found 
among avian NS1 (residues 212 to 217) but rarely among human isolates. Of the four human isolates 
that possess this motif, three were due to zoonotic transmissions to humans [30]. SH3 domains are 
small protein modules that mediate protein-protein interactions and are often found in proteins that 
regulate cellular signalling pathways, cytoskeletal organization and membrane trafficking. It is 
hypothesized that exploiting the cellular signalling machinery of the host might provide viruses that 
possess these SH3-binding motifs with increased replicative ability and/or pathogenicity.  
2.5. Carboxy terminal truncations and elongations 
As mentioned previously the c-terminal of the NS1 protein has been implicated in the enhancement 
of the protein’s interferon antagonist properties by stabilizing its dimeric structure [7,8]. The   
c-terminal also possesses an effector domain that can inhibit 3'-end processing of cellular pre-mRNA 
by interaction with the 30kDA subunit of the cleavage and polyadenylation factor (CPSF) and can 
prevent transport of cellular mRNA to the cytoplasm by interaction with the poly(A)-binding protein II 
(PABII) [17,31]. In addition, the c-terminal has been shown to have one of two nuclear location 
signals (NLS) that play an important role in the entry and accumulation of the protein in the nuclei of 
infected cells [32,33]. More recently, Melén et al. [33] located the precise residues that make up the 
NLS2 and have also identified a nucleolar localization signal (NoLS) sequence that shares residues 
with NLS2. 
Studies of the NS1 protein of H7N1 and H7N3 avian influenza isolates from Italy and Pakistan have 
revealed truncations of the carboxy terminal of the protein following extensive circulation in poultry 
[34,35]. In order to determine whether these truncations were confined just to AI viruses of the H7 
subtype we have carried out a detailed analysis of 7,141 NS1 proteins sequences from influenza A Viruses 2009, 1                      
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viruses of avian, equine, human, and swine origin deposited in the public databases and accessible 
through the Influenza Virus Resource (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html)   
(up to August 2009).  
Table 1. Length variation types (LVTs) in the NS1 protein of influenza A viruses (August 2009). 
NS1 length aa (LVT) 
Species Subtype  202  212 215 217 219 220 223 224 225  230  232  237  Total 
Avian  H1N1      6       71     77 
Avian  H1N2      2       5     7 
Avian  H3N2       14        49     63 
Avian  H3N8      1       108      109 
Avian  H4N6  1    1      101      103 
Avian  H4N8             34   1  35 
Avian  H5N1    2    8     72  1123 78 6    1289 
Avian  H5N2      17        144      161 
Avian  H5N9  2           4     6 
Avian  N6N1  1    70         83     154 
Avian  H6N2      42         79     121 
Avian  H7N1 1         11  34    33      79 
Avian  H7N2      1      156      157 
Avian  H7N3      30        107    1  138 
Avian  H9N2      393  3      171      567 
Avian  H13N2              3   1  4 
Human  H1N1  3    3  509*      720    104  1339 
Human H2N2        1    13        2    74  90 
Human  H3N2      2  9       1825    167  2003 
Human  H5N1     2        125  17     144 
Human  H9N2      1        4     5 
Swine  H1N1      5  109        53   3  170 
Swine  H1N2      3  66        14     83 
Swine  H2N3      2             2 
Swine  H3N1      5       1     6 
Swine  H3N2      6  34        48  11  99 
Equine  H3N8      2  40        88     110 
  Total  8  2  2 582 791 36 72 34 1248 3998 6  362  7141 
* Swine origin pandemic H1N1 
 
Overall, seven length variation types (LVTs) from the wild-type length of 225/230 aa can be 
identified. These LVTs consist of a 2 [LVT(-2)], 6 [LVT(-6)], 10 [LVT(-10)], 11 [LVT(-11)], 13 aa 
[(LVT(-13)] or 28 aa [(LVT(-28)] c-terminal truncation or a 7 aa [LVT(+7)] elongation resulting in 
proteins of 223 aa (for H5N1 viruses only), 224 aa, 220 aa (215 aa for some H5N1 viruses), 219 aa, Viruses 2009, 1                      
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217 aa (212 aa for H5N1 viruses), 202 aa and 237 aa (232 aa for H5N1 viruses) respectively   
(Table 1 and Figure 1). 
Figure 1. Schematic representation of the length variation types (LVTs) identified in the 
NS1 protein. The consensus sequence of avian influenza NS1 proteins are shown. Amino 
acids from the NLS2/NoLS [32,33] are shown in bold red while the PL motif [24] is 
doubly underlined.  
                         200                          210                         220                          230            
                        (195)                        (205)                     (215)                        (225) 
                           |                                |                              |                               | 
----ETLQRFAWRSSNEDGRPPLPPKQKRQMARTIESEV*   
----ETLQRFAWRSSNEDGRPPLPPKQKRQMARTIES*   LVT(-2) 
----ETLQRFAWRSSNEDGRPPLPPKQKRQMAR*               LVT(-6) 
----ETLQRFAWRSSNEDGRPPLPPKQKR*                  LVT(-10) 
----ETLQRFAWRSSNEDGRPPLPPKQK*   LVT(-11) 
----ETLQRFAWRSSNEDGRPPLPPK*   LVT(-13) 
----ETLQRFA*   LVT(-28) 
----ETLQRFAWRSSNEDGRPPLPPKQKRQMARTIESEVRRNKMAD*   LVT(+7) 
   
 
Analysis of the nucleotide sequence reveals that all the truncated proteins are the result of a single 
base change resulting in the creation of a stop codon except for the 6 aa truncation which is the result 
of two nucleotide changes in the same codon. The 7 aa elongations are due to the creation of an amino 
acid from a stop codon by a single nucleotide change.  
The LVT(-2) was identified in avian H5N1 viruses only. Specifically, the 2 aa truncation was seen 
among a group of 72 H5N1 AI viruses isolated between 2004 to 2006 in Vietnam, Hong Kong and 
China [36,37]. Although the authors undertook a detailed phylogenetic analysis of these viruses no 
comment was made on the length variation of the NS1 proteins. It is of particular interest as the 
truncation involves the PL (PDZ ligand) motif described by Obenauer et al. [24]. As mentioned above, 
Jackson et al. [26] investigated the effect of changes to the PL motif in the mouse model using reverse 
genetics by creating several recombinant viruses, one of which completely lacked the 4 c-terminal 
amino acids of the PL motif. This recombinant viruses displayed an attenuated phenotype when 
compared to recombinant viruses with an intact PL motif when tested for viral growth kinetics and in a 
mouse infection model. It would therefore be expected that the H5N1 viruses with a LVT(-2) would 
also behave differently from viruses with an intact PL motif and this observation merits further 
investigation.  
The LVT(-6) is also only found in one group of viruses, namely, the avian influenza H7N1 viruses 
isolated from domestic poultry in Northern Italy between 1999 and 2001 [34]. The 6 aa truncation is 
due to a mutation of a threonine at position 225 to a stop codon. This mutation involves changing two Viruses 2009, 1                      
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nucleotides within the same codon and this may explain why LVT(-6) has not been identified in other 
influenza A viruses given that a double mutation is a much rarer event. Of note is that, compared to the 
H7N1 isolates with a non-truncated protein which were all of low pathogenicity, all of the viruses with 
a LVT(-6) were highly pathogenic and caused severe disease in domestic poultry. Whether the 
truncated NS1 plays a role in this increased pathogenicity is presently unknown.  
The LVT(-10) was identified in human (H2N2, H3N2 and H5N1) and avian (H7N1 and H9N2) but 
not in equine and swine influenza A viruses. The presence of the 10 aa truncation in the human H2N2 
and H3N2 is confined to the 5 year period between 1967 and 1972 and has not been seen since [38]. 
The two human H5N1 viruses of avian origin are of particular interest. This truncation completely 
removes the PL motif described by Obenauer et al. [24]. One of these H5N1 viruses   
(A/Viet Nam/1203/2004) has previously been shown by Govorkova et al. [39] to be particularly 
virulent in the ferret model suggesting that, although the avian like PL motif seems to play a role in the 
pathogenesis of H5N1 viruses, it does not appear to be a prerequisite for virulence [26]. Additional 
analysis of virus A/Viet Nam/1203/2004 using reverse genetics showed that by replacing the 220 aa 
NS1 protein with a full-length 225 aa NS1 protein the virus was significantly attenuated in a ferret 
model suggesting an important role for this 10 aa truncation in the pathogenesis of H5N1 viruses [40].  
A small number of H9N2 avian influenza isolates also possess the LVT(-10). These viruses are part 
of a group of seven homogeneous isolates from chicken (n=4) and quail (n=3) obtained in the United 
Arab Emirates and studied by Amir et al. [41]. Interestingly, the quail isolates, which did not produce 
any overt clinical signs in the field, all had a full-length 230 aa long NS1. In contrast, the chicken 
isolates were characterised by general congestion, severe tracheitis and acute onset mortality and three 
out of four of them had an NS1 with LVT(-10). In challenge experiments it was also shown by Amir  
et al. [41] that there was a clear biological difference between the quail and chicken isolates; the quail 
isolates replicated in chickens but failed to transmit to contact birds while the chicken isolates both 
replicated and transmitted to contact birds. It is possible that NS1 plays a role in the transmission of 
the virus and so the non-chicken adapted strain had more difficulty transferring to chickens. Although 
the sample group is small, it is tempting to think that the results of Amir et al. [41], with specific 
reference to the NS1, is also evidence for host adaptation from quail to chicken.  
LVT(-11) is found predominantly in swine origin viruses; that is the classical swine influenzas of 
subtypes H1N1, H1N2 and H3N2 and the presently circulating human pandemic H1N1 virus. There 
are, however, a small number (n=24) of avian influenza viruses, one of which is of swine origin  
(e.g., A/turkey/Chile/28317-6504-3/2009) and a slightly larger number (n=40) of equine H3N8 that 
posses an NS1 of 119 aa. Interestingly, a further analysis of the NS1 nt sequences from these viruses 
reveals that there is no phylogenetic relationship between the NS1 originating from swine and those 
from horses indicating that these truncations are not due to random mutational events. The 
characteristics of NS1 proteins with a LVT(-11) would be expected to be very similar to those 
possessing a LVT(-10) but to date there is no biological data available for this group of viruses. Given 
the interest in pandemic H1N1 a further characterization of the truncated NS1 would be opportune.  
The LVT(-13) is the most common of the variations in the NS1 protein with seven avian influenza 
subtypes possessing it. The majority of the H9N2 (69%) subtype viruses analysed possess the 13 aa 
truncation. Of the avian H6N1 viruses that possess the LVT(-13), all were isolated in China or Hong 
Kong from minor poultry species (e.g. quail, chukar, guinea fowl, partridges and pheasants) from 2000 Viruses 2009, 1                      
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to 2005 [42]. Of interest is that in this study only one H6N1 AI virus was isolated from 8,788 chicken 
specimens examined suggesting that the H6N1 viruses with a LVT(-13) truncated proteins can infect 
minor poultry species more easily than chickens.  
For the H7N3 viruses with the LVT(-13) all except one were isolated in Pakistan and Afghanistan 
between 1995 and 2005 [35]. In this study we also identified two Pakistani H7N3 viruses with a 230 aa 
NS1 that were genetically distinct from the viruses with a truncated protein indicating that within the 
H7N3 Pakistan virus populations there were at least three viral subpopulations that circulated in the  
10 year period investigated. All of the viruses were highly pathogenic causing severe disease in 
poultry [43]. The LVT(-13) removes a significant number (n=4) of residues from the NLS [32,33] in 
addition to the binding site of PABII [31]. Despite this, it is the most common LVT found among 
influenza A viruses clearly questioning the significance of PABII binding and the NLS in the 
pathogenesis and transmission of these viruses.  
LVT (-28) was only observed in avian (n=5) and human H1N1 (n=3) isolates. This is the largest of 
the truncation removing over 12% of the protein and was first described in the two human isolates by 
Kyrstal et al. [44]. The removal of such a significant stretch of the c-terminal of the protein would be 
expected to have an effect on the stability of the dimeric structure which in turn would alter the 
interferon antagonist properties of the NS1 as described by Wang et al. [8]. It is possible that given the 
low number (n=8) of isolates identified with this 28 aa truncation that this LVT is a laboratory artefact 
due to passaging in cells or embryonated eggs. It has already been reported that large c-terminal 
deletions can be tolerated by influenza A when grown in eggs or cell culture [45]. It would be of 
interest to investigate the ability of the NS1 proteins from these virus to dimerize and abrogate IFN 
production in infected cells. 
Only eight AI viruses have the 7 aa elongation which is predominant among human H1N1 and 
H2N2 isolates. These AI viruses are a wild bird isolate of the H13N2 subtype, a chicken H7N3 virus 
isolated in our laboratory from Northern Italy in 2007 and six H5N1 viruses originating from Vietnam 
and China in 2003 and Nigeria in 2006. A more detailed sequence analysis of the PL motif of each of 
the virus reveals that the Vietnamese, Italian and wild bird isolates all have the avian-like ESEV motif 
followed by the 7 aa extension. Jackson et al. [26] created a recombinant virus with an avian-like 
ESEV motif followed by a 7 aa extension. This recombinant viruses, however, proved to be attenuated 
in both growth kinetics and in infection of mice. These results therefore suggest that avian viruses with 
LVT(+7) elongated NS1 proteins may not replicate in other species as readily as viruses with shorter 
NS1 proteins. Indeed, given the large number of human isolates with LVT(+7) the host would appear 
to be important in determining whether the NS1 protein is elongated or not.  
An analysis of the NS1 sequence data available has clearly shown that the length variations seen 
between influenza A viruses isolated from different species in not a random event. Given the fact that 
it is not a random event, the removal or addition of specific amino acid residues at the c-terminal of the 
protein must in some way confer an advantage or disadvantage on the viruses. In some of the 
truncations seen the PL, NLS and the PABII binding sites are directly effected but it is not clear at 
present to what extent this alters pathogenicity or transmission of the viruses that posses them. Indeed 
there is conflicting evidence that suggests that the PL is probably not an essential virulence factor for 
influenza A viruses. In this review we have listed several examples of highly pathogenic H7 and H5 Viruses 2009, 1                      
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viruses that have truncations that remove the PL but still maintain their pathogenicicty. Further work 
on the PL domain is therefore required to resolve this question.  
3. NS1 and vaccination 
Highly pathogenic avian influenza (HPAI) is a devastating disease that has caused enormous 
economic losses in the poultry industry worldwide. International organisations have issued a series of 
recommendations aimed at controlling AI [46]. In addition to direct control measures based on 
biosecurity, restriction policies and stamping out, the appropriate use of vaccines is encouraged to 
maximise eradication efforts. Historically the use of vaccination against AI has been discouraged or 
banned as it was feared that it would prevent the rapid diagnosis of the disease by hiding clinical 
manifestations in poultry.  
A number of different types of vaccination strategies for AI are now available [46]. These range 
from conventional inactivated vaccine using low pathogenicity avian influenza (LPAI) virus with 
homologous HA to the field virus, to genetically engineered or reassortant viruses to DNA vaccination 
[46]. 
It is known that blocking or reducing the function of the NS1 can attenuate the influenza virus by 
allowing the host to generate a strong interferon response against the virus [1-3]. Attenuated viruses 
are ideal candidates for live-attenuated vaccines which have the added advantages over inactivated 
vaccines of triggering mucosal immune responses and inducing cell mediated immunity in the host. 
For this reason a number of different groups have been focusing their attention on the development of 
vaccines based on the genetic manipulation of the ns1 gene  
Wang et al. [47] recently investigated the potential use of a series of reassortant viruses that had 
various deletions in their ns1 genes. By passaging a well characterised virus (A/Turkey/Oregon/71) 
with a previously identified 10 nucleotide deletion in the ns1 gene they were able to clone and identify 
more that 20 ns1 genes of different sizes. All of these ns1 genes variants were selected and nine 
reassortant viruses were created and characterised further. The reassortants were tested for their 
protective ability in SPF chickens following challenge with a heterologous virus of the same HA 
subtype and it was clearly shown that two of the reassortant viruses could be used as potential live 
attenuated vaccines in poultry.  
Zhirnov et al. [48] have determined the protective efficacy of DNA vaccination in poultry using a 
combination of conserved proteins namely the matrix (M1) and nucleoprotein (NP). However, the 
authors observed that by including an NS1-encoding plasmid as part of the M1/NP immunization 
protocol they could significantly improve protection to virus challenge in mice and chickens. Although 
not confirmed by the authors, this effect is most likely due to the induction of cellular immunity to the 
NS1, a response which has previously been reported in human peripheral blood mononuclear cells 
[49]. 
Similar work has been carried out by Steel et al. [50]. In this report the authors created a set of 
experimental live-attenuated vaccines based on a recombinant H5N1 virus (A/Viet Nam/1203/04) with 
a glutamic acid at the residues 627 of the PB2 and one of a series of truncated NS1 proteins. A 
recombinant vaccine with a 99 aa long NS1 protein completely protected chickens from lethal Viruses 2009, 1                      
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challenge from both a homologous (A/Viet Nam/1203/04) and heterologous (A/egret/Egypt/01/06) 
H5N1 virus confirming the potential of such vaccines in the control of avian influenza 
4. NS1 DIVA 
It is known that vaccination prevents clinical disease, increases resistance to infection and reduces 
virus shedding levels, but does not prevent infection if birds are challenged with a sufficiently high 
dose of virus [51,52]. For this reason, vaccinated birds may still become infected and shed virus into 
the environment without displaying any clinical signs, and therefore they represent a means of 
spreading infection. 
In order, therefore, to support eradication efforts of AI infections in poultry, the implementation of 
“DIVA” vaccination strategies, enabling the Differentiation of Infected from Vaccinated Animals have 
been recommended by international organizations like the OIE (World Organization for Animal 
Health) and FAO (United Nations Food and Agricultural Organization). These systems allow for the 
detection of field exposure in vaccinated flocks and through this, infected flocks may be properly 
managed, thus interrupting the perpetuation of the infectious cycle.  
Several “DIVA” systems have been developed to date although they have some limitations in the 
field [53-57]. A promising system, based on the detection of antibodies against the NS1 of AI has been 
deemed a good candidate [58-59]. The NS1 protein is synthesized in large amounts in infected cells 
but is not incorporated into the mature virions, and for this reason represents the ideal candidate to 
elicit a specific immune response only in the presence of active viral replication.  
A paper by Birch-Machin et al. [60] reported that antibodies to NS1 could be detected in serum 
samples of ponies experimentally infected with equine influenza virus, but not in animals vaccinated 
with whole inactivated virus. Likewise a study by Ozaki et al. [61] identified antibodies to the NS1 
exclusively in the sera of mice infected with equine influenza viruses and not in those mice immunized 
with inactivated virus. 
A number of groups have investigated the feasibility of a NS1 DIVA for AI. Tumpey et al. [58] 
experimentally infected poultry and evaluated their ability to induce antibodies reactive to NS1 
recombinant protein produced in Escherichia coli or to chemically synthesized NS1 peptides. Immune 
sera were obtained from chickens and turkeys inoculated with live AI virus, inactivated purified 
vaccines, or inactivated commercial vaccines. Seroconversion to positivity for antibodies to the NS1 
protein was achieved in birds experimentally infected with multiple subtypes of influenza A virus, as 
determined by enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. In contrast, 
animals inoculated with inactivated gradient-purified vaccines had no seroconversion to positivity for 
antibodies to the NS1 protein, and animals vaccinated with commercial vaccines had low, but 
detectable, levels of NS1 antibodies. The use of a second ELISA with diluted sera identified a 
diagnostic test that results in seropositivity for antibodies to the NS1 protein only in infected birds. For 
the field application phase of this study, serum samples were collected from vaccinated and infected 
poultry, diluted, and screened for anti-NS1 antibodies. Field sera from poultry that received 
commercial AI vaccines were found to possess antibodies against AI virus, as measured by the 
standard agar gel precipitin (AGP) test, but they were negative by the NS1 ELISA. Conversely, diluted 
field sera from AI-infected poultry were positive for both AGP and NS1 antibodies.  Viruses 2009, 1                      
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Another study by Zhao et al. [59] reported the development of a similar ELISA based DIVA 
strategy to differentiate AI-infected chickens versus chickens immunized with inactivated avian 
influenza virus. A recombinant nonstructural protein (NS1) cloned from an H9N2 AI virus was 
expressed and purified from Escherichia coli and used as the diagnostic antigen. Similar to the study 
by Tumpey et al. [58], antibodies to the NS1 protein were only detected in the sera of chickens 
experimentally infected with AI but not in the sera of chickens immunized with inactivated vaccine.  
One of the limitation of the NS1 DIVA approach is the purity of the vaccines used. Commercial 
vaccines are normally only partially purified and so, although inactivated, they may contain residual 
NS1 protein which can, in turn, effect the performance and interpretation of an ELISA design to detect 
antibodies to NS1. Indeed, from the work of Zhao et al. [59] there is an indication that the vaccine they 
used in their study was unsuitable for the above reason. Likewise, these authors, by intravenously 
challenging their experimental birds with virus, failed to mimic field infection dynamics and possibly 
induced a stronger immune response to the NS1 protein.  
Some work has been performed to determine the onset of the antibody response in chickens and 
turkeys to the NS1 protein. The data obtained indicate that the duration of the antibody response and 
the variability between species may detract from the performance and utility of an NS1 DIVA strategy 
[62,63]. So, despite the apparently promising results from the work by Tumpey et al. [58] and   
Zhao  et al. [59], further work needs to be undertaken and full field validation under different 
circumstances is required before an NS1 DIVA strategy can be proposed to the veterinary community.  
5. Conclusion 
The NS1 is a fascinating protein with a surprisingly large number of functions ascribed to it for a 
relatively small protein. The resolution of the three dimensional structure has gone a long way in 
explaining the multifunctionality of the protein. Likewise, the huge increase in influenza A genomes 
that are being sequenced has allowed the influenza community to identify similarities and differences 
between viruses that infect birds and those that infect mammals. Despite this many questions remained 
unanswered particularly in relation to the observed deletions and truncations that are stably maintained 
by the viruses that possess them. An eventual explanation for these phenomena will no doubt add a 
further understanding of NS1s involvement in the biology of influenza A viruses. 
Developments in vaccine strategies using the NS1 are ongoing and should provide good alternatives 
for the control of Avian influenza. They will, however, require complete field validation and the 
existence of validated companion kits before they become part of routine control strategies for AI.  
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